Entrada Therapeutics Insider 5AM Trims Position by 2.8%
Rhea-AI Filing Summary
Form 4 filings dated 07/01/2025 disclose that venture–backed funds affiliated with 5AM Venture Management, a 10 % beneficial owner of Entrada Therapeutics (TRDA), executed a three-day program of open-market sales. The entities involved were 5AM Ventures V, L.P. (direct holder) and 5AM Opportunities I, L.P. (indirect holder). The sales were made on 06/27, 06/30 and 07/01 at prices ranging from $6.81 – $7.12 per share.
- Shares sold by 5AM Ventures V: 92,891 shares (55,735 + 18,578 + 18,578) for proceeds of roughly $639k.
- Shares sold by 5AM Opportunities I: 32,109 shares (19,265 + 6,422 + 6,422) for proceeds of roughly $220k.
- Total shares sold: 125,000 shares, representing about 2.8 % of the combined 4.41 million-share position held prior to the first transaction.
After the transactions, 5AM Ventures V holds 3,183,131 shares directly, while 5AM Opportunities I holds 1,100,248 shares indirectly, leaving the 5AM group with an aggregate stake of approximately 4.28 million shares. All reporting persons—5AM Partners V, 5AM Opportunities I (GP), and managing members Dr. Scott M. Rocklage and Andrew J. Schwab—remain classified as 10 % owners. No derivative securities were reported.
The filing signals modest insider selling by a large shareholder following a minor upward move in TRDA’s share price during the period. Although the group maintains a substantial ownership position, the reduction could be interpreted by investors as a slight negative sentiment shift or portfolio rebalancing.
Positive
- 5AM group retains a large 4.28 million-share position, indicating continued strategic interest in TRDA.
Negative
- Insider selling of 125,000 shares by a 10 % owner can be perceived as a bearish signal and may create near-term supply pressure.
Insights
TL;DR: 10 % owner trims 2.8 % of stake; modest bearish signal, impact limited by retained 4.28 m-share position.
The 5AM funds liquidated 125k shares over three consecutive sessions at an average price just above $6.9. Volumes are small relative to both 5AM’s remaining stake and TRDA’s typical daily volume, suggesting opportunistic profit-taking rather than a wholesale exit. However, insider sales by a control holder can pressure sentiment, especially in micro-cap biotech names where ownership concentration is high. No complementary purchases or option exercises offset the sales, so the net insider activity is negative. Investors should monitor whether further Form 4s show a pattern.
TL;DR: Sales are immaterial to ownership control but add short-term overhang; not thesis-changing.
Even after selling, the 5AM entities control more than 4 million shares, keeping them comfortably above the 10 % threshold. The transaction value (~$0.86 m combined) is negligible versus typical venture-fund recycling. The gradual price uptick from $6.81 to $7.12 during execution implies adequate liquidity and no urgency. Unless the divestment accelerates, I classify the disclosure as not impactful to long-term fundamentals but potentially weighing on near-term technicals.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 18,578 | $7.1226 | $132K |
| Sale | Common Stock | 6,422 | $7.1226 | $46K |
| Sale | Common Stock | 18,578 | $6.8127 | $127K |
| Sale | Common Stock | 6,422 | $6.8127 | $44K |
| Sale | Common Stock | 55,735 | $6.91 | $385K |
| Sale | Common Stock | 19,265 | $6.91 | $133K |
Footnotes (1)
- Shares are held by 5AM Ventures V, L.P. ("5AM V"). 5AM Partners V, LLC ("5AM Partners") is the sole general partner of 5AM V. Dr. Kush Parmar, Andrew J. Schwab and Dr. Scott M. Rocklage are managing members of 5AM Partners and may be deemed to have shared voting and investment power over the shares beneficially owned by 5AM V. Each of 5AM Partners, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of the shares of Common Stock held by 5AM V, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the Issuer and files separate Section 16 reports. Shares are held by 5AM Opportunities I, L.P. ("Opportunities"). 5AM Opportunities I (GP), LLC ("Opportunities GP") is the sole general partner of Opportunities. Andrew J. Schwab and Dr. Kush Parmar are managing members of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities. Each of Opportunities GP and Mr. Schwab disclaims beneficial ownership of the shares of Common Stock held by Opportunities, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the Issuer and files separate Section 16 reports.
